Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amgen Inc. stock logo
AMGN
Amgen
$305.85
+1.6%
$287.82
$211.71
$329.72
$164.07B0.62.73 million shs4.49 million shs
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$64.27
+0.3%
$67.55
$62.07
$87.86
$80.07B0.225.79 million shs14.51 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$142.55
-5.9%
$120.42
$62.55
$170.47
$54.63B1.574.43 million shs7.18 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.66
+1.6%
$27.35
$25.20
$40.37
$162.40B0.6335.43 million shs78.29 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amgen Inc. stock logo
AMGN
Amgen
0.00%+0.00%+9.86%+9.10%+38.61%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.00%-2.15%-1.62%-11.12%-16.47%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-14.44%+13.50%+49.96%+11.62%
Pfizer Inc. stock logo
PFE
Pfizer
-0.07%-0.76%+3.47%+7.78%-24.62%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amgen Inc. stock logo
AMGN
Amgen
4.5213 of 5 stars
2.33.03.33.92.52.51.9
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
4.9495 of 5 stars
4.23.03.34.11.82.51.9
Moderna, Inc. stock logo
MRNA
Moderna
3.3333 of 5 stars
2.11.00.04.63.03.30.6
Pfizer Inc. stock logo
PFE
Pfizer
4.8113 of 5 stars
3.23.04.24.81.51.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amgen Inc. stock logo
AMGN
Amgen
2.52
Moderate Buy$305.65-0.07% Downside
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.35
Hold$83.6930.21% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.24
Hold$126.46-11.29% Downside
Pfizer Inc. stock logo
PFE
Pfizer
2.40
Hold$35.8625.11% Upside

Current Analyst Ratings

Latest AMGN, GILD, MRNA, and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2024
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageIn-Line$120.00
5/13/2024
Moderna, Inc. stock logo
MRNA
Moderna
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
5/9/2024
Amgen Inc. stock logo
AMGN
Amgen
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$223.00 ➝ $235.00
5/7/2024
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$143.00 ➝ $151.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$284.00 ➝ $307.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$271.00 ➝ $310.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$332.00 ➝ $328.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$336.00 ➝ $355.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Equal Weight$230.00 ➝ $300.00
5/3/2024
Amgen Inc. stock logo
AMGN
Amgen
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
5/3/2024
Moderna, Inc. stock logo
MRNA
Moderna
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$91.00 ➝ $106.00
(Data available from 6/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amgen Inc. stock logo
AMGN
Amgen
$28.19B5.82$26.37 per share11.60$9.36 per share32.68
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$27.12B2.95$8.95 per share7.18$14.01 per share4.59
Moderna, Inc. stock logo
MRNA
Moderna
$6.85B7.98N/AN/A$33.44 per share4.26
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.78$2.98 per share9.63$16.33 per share1.76

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amgen Inc. stock logo
AMGN
Amgen
$6.72B$7.0043.6914.872.7612.74%156.21%10.82%8/1/2024 (Estimated)
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$5.67B$0.36178.538.881.291.76%24.34%8.36%8/1/2024 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$4.71B-$15.67N/AN/AN/A-115.82%-20.10%-15.00%8/1/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B-$0.06N/A10.421.13-0.56%8.64%3.70%8/6/2024 (Estimated)

Latest AMGN, GILD, MRNA, and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024Q1 2024
Amgen Inc. stock logo
AMGN
Amgen
$3.76$3.96+$0.20$8.13$7.45 billion$7.45 billion    
5/2/2024Q1 2024
Moderna, Inc. stock logo
MRNA
Moderna
-$3.59-$3.07+$0.52-$3.07$93.26 million$167.00 million    
5/1/2024Q1 2024
Pfizer Inc. stock logo
PFE
Pfizer
$0.56$0.82+$0.26$1.09$13.87 billion$14.88 billion    
4/25/2024Q1 2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
-$1.49-$1.32+$0.17$0.70$6.36 billion$6.69 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amgen Inc. stock logo
AMGN
Amgen
$9.002.94%+10.01%128.57%13 Years
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.084.79%+3.32%855.56%9 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.685.86%+2.57%N/A 15 Years

Latest AMGN, GILD, MRNA, and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/23/2024
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Quarterly$0.774.71%6/14/20246/14/20246/27/2024
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
3/6/2024
Amgen Inc. stock logo
AMGN
Amgen
quarterly$2.253.25%5/16/20245/17/20246/7/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amgen Inc. stock logo
AMGN
Amgen
11.96
1.42
0.98
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.31
1.08
0.94
Moderna, Inc. stock logo
MRNA
Moderna
0.04
4.03
3.91
Pfizer Inc. stock logo
PFE
Pfizer
0.66
1.05
0.78

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Amgen Inc. stock logo
AMGN
Amgen
76.50%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
83.67%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Amgen Inc. stock logo
AMGN
Amgen
0.69%
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.16%
Moderna, Inc. stock logo
MRNA
Moderna
15.70%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Amgen Inc. stock logo
AMGN
Amgen
26,700536.43 million532.73 millionOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
18,0001.25 billion1.24 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,600383.24 million323.07 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.67 billion5.66 billionOptionable

AMGN, GILD, MRNA, and PFE Headlines

Recent News About These Companies

3 Discounted Stocks Poised for a Major Upswing
Pfizer (NYSE:PFE) Trading Up 1.6%
Is Pfizer the Best Dividend Stock for You?
Pfizer (NYSE:PFE) Shares Up 0.3%
3 Dividend Stocks to Double Up on Right Now

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Amgen logo

Amgen

NASDAQ:AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Gilead Sciences logo

Gilead Sciences

NASDAQ:GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.